Table 1 |
|||
|
Baseline (2000) characteristics of the patients in EMECAR |
|||
| Characteristic |
All studied patients |
Ever used aTNF or LEF |
Never used aTNF or LEF |
|
|
|||
| n |
789 |
210 (27%) |
579 (73%) |
| Women |
568 (72) |
159 (76)* |
409 (71) |
| Age (years) |
61 ± 13 |
57 ± 12*** |
63 ± 13 |
| Age at rheumatoid arthritis onset (years) |
48 ± 15 |
44 ± 13*** |
50 ± 15 |
| Rheumatoid factor-positive |
592 (75) |
167 (79)** |
346 (70) |
| Any comorbidity |
606 (77) |
154 (73) |
380 (77) |
| Any extra-articular rheumatoid arthritis |
355 (45) |
122 (58)* |
226 (46) |
| Health Assessment Questionnaire score |
1.2 ± 0.9 |
1.3 ± 0.8 |
1.2 ± 0.9 |
| Disease activity score from 28-joint count with three parameters |
4.1 ± 1.4 |
4.6 ± 1.4*** |
3.9 ± 1.3 |
| Larsen score |
54 ± 27 |
57 ± 24 |
53 ± 27 |
|
|
|||
|
Data presented as n (%) or as mean ± standard deviation. Characteristics of those patients who used TNF antagonists (aTNF) or leflunomide (LEF) at any time of follow-up were compared with those of patients who did not. ***P < 0.001, **P < 0.01, *P < 0.05. |
|||
|
González-Alvaro et al. Arthritis Research & Therapy 2008 10:R138 doi:10.1186/ar2561 |
|||
